Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Arie Belldegrun
Biotech
4 years on from launch, IconOVir sells oncolytic virus to UroGen
UroGen is paying IconOVir Bio $4 million in stock for an early-phase oncolytic virus that could work like a turbocharged BCG therapy.
Nick Paul Taylor
Feb 20, 2025 9:12am
Life science credit firm unveils with $600M
Aug 6, 2024 10:30am
Belldegrun's VC firm nabs a major $825M funding well
Jun 24, 2021 7:15am
Ginkgo lands on NYSE via $2.5B SPAC merger
May 11, 2021 8:10am
IconOVir uncloaks with $77M, ex-Forty Seven CEO
Jan 5, 2021 6:00am
ASCO: Allogene's off-the-shelf CAR-T shows hints of efficacy
May 13, 2020 5:00pm
